To join this case, fill out the form below
By clicking on the Submit button below, I acknowledge that I have read the Retainer Agreement and agree to retain WeissLaw LLP to file an action against the Company in connection with this matter. WeissLaw LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses.
By clicking on the Submit button below, I acknowledge that I have read the Derivative Retention Letter and agree to retain WeissLaw LLP to file an action against the Company in connection with this matter. WeissLaw LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses.
A signed Retainer Agreement will be sent to your email shortly.
Oops! Something went wrong while submitting the form.

IVERIC bio, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of IVERIC bio, Inc. (“IVERIC” or the “Company”) (NASDAQ: ISEE), in connection with its proposed acquisition by Astellas Pharma Inc.  Under the merger agreement, the Company’s shareholders will receive $40.00 in cash for each share of IVERIC owned.  The transaction is valued at approximately $5.9 billion.

Weiss Law is investigating whether (i) IVERIC’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $40.00 per share merger consideration adequately compensates IVERIC’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

Other Cases